Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company’s products are based on the EVade™ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The EVade™ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company's lead candidate, QBI-139, is in a Phase I human clinical trial at the University of Texas M. D. Anderson Cancer Center and the University of Wisconsin Comprehensive Cancer Center.
View Top Employees from Quintessence Biosciences, Inc.Website | http://www.quintbio.com |
Revenue | $1.2 million |
Employees | 4 (1 on RocketReach) |
Founded | 2000 |
Address | 3300 Commercial Avenue, Madison, Wisconsin 53714, US |
Phone | (608) 441-2950 |
Fax | (608) 441-2952 |
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Drug Manufacturing & Research, Health Care, Science and Engineering, Therapeutics |
SIC | SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Quintessence Biosciences, Inc. employee's phone or email?
The Quintessence Biosciences, Inc. annual revenue was $1.2 million in 2024.
1 people are employed at Quintessence Biosciences, Inc..
Quintessence Biosciences, Inc. is based in Madison, Wisconsin.
The NAICS codes for Quintessence Biosciences, Inc. are [3254, 32541, 32, 325].
The SIC codes for Quintessence Biosciences, Inc. are [2834, 28, 283].